Stay updated on Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The study page now communicates that recruitment has ended and adds new guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) while adjusting the Interventions header and noting a new revision tag (Revision: v3.6.0).
    Difference
    0.4%
    Check dated 2026-06-13T00:31:45.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.5.5, replacing the previous v3.5.4. This reflects a minor update to the study page documentation or display framework rather than to the study details themselves.
    Difference
    0.1%
    Check dated 2026-06-05T21:55:07.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    29 days ago
    Change Detected
    Summary
    No additions or deletions were found. The page content appears unchanged.
    Difference
    0.1%
    Check dated 2026-05-22T16:07:03.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    The revision label on the page has been updated from v3.5.3 to v3.5.4, signaling a newer version of the document. This change reflects an updated version identifier rather than any user-facing content edits.
    Difference
    0.1%
    Check dated 2026-05-15T14:22:34.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    The page footer revision/version was updated from v3.5.2 to v3.5.3, indicating a site release/version change rather than an update to the clinical study record details.
    Difference
    0.1%
    Check dated 2026-04-24T06:09:23.000Z thumbnail image
  7. Check
    64 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2; Deleted Revision: v3.5.0.
    Difference
    0.1%
    Check dated 2026-04-17T02:31:53.000Z thumbnail image

Stay in the know with updates to Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.